UK 19:29 Monday, 19 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
It has been too long since I revisited AIM-listed biotech Scancell (SCLP). Much has happened since I picked it as a share for 2015 but it is egg-on-face as the shares have more than halved, with (so far) no value-enhancing corporate deal on the table. The clinical trial on the company’s lead product, SCIB-1, is done but there have been funding questions – correctly called by Tom Winnifrith. Now we have an EIS-qualifying open offer on the table alongside a placing, with some detail of plans going forward. Still holding my shares, the question is what to do?
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments
alcira16247
Nigel
Thanks for a great article.
I sold out @27.5p back of last summer, following Tom’s story on an imminent placing. It was a ruddy good decision as ever since the share has gone south.
Would I reinvest, even at current levels? No, I don’t think I would……
Cynically, if the company really did have such ground breaking new science in fighting the targeted cancers, wouldn’t have a major pharmaceutical, stepped in offering an joint venture partnership or bidding outright for the company, by now?
I don’t like the apparent greed of the directors in awarding themselves options for other than doing what they get well paid for doing…ie. running the bloody company!
I sincerely wish the company all success in their endeavours, but for me, as an investment, nope.